Inozyme Pharma Ownership 2024 | Who Owns Inozyme Pharma Now?


OverviewForecastRevenueFinancialsChart

Institutional Ownership

96.21%

Insider Ownership

0.52%

Retail Ownership

3.27%

Institutional Holders

91.00

Inozyme Pharma Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ADAGE CAPITAL PARTNERS GP, L.L.C.10.28%0.08%5,328,856-208,644-3.77%40,819,037Mar 31, 2024
PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC8.67%22.13%4,494,851--34,430,559Mar 31, 2024
SOFINNOVA INVESTMENTS, INC.8.26%1.83%4,280,308--32,787,159Mar 31, 2024
ROCK SPRINGS CAPITAL MANAGEMENT LP7.10%0.72%3,681,174--28,197,793Mar 31, 2024
EVENTIDE ASSET MANAGEMENT, LLC6.13%0.38%3,179,837--24,357,551Mar 31, 2024
BLACKROCK INC.5.96%0.00%3,088,65346,3231.52%23,659,082Mar 31, 2024
SAMLYN CAPITAL, LLC5.62%0.37%2,912,913-459,645-13.63%22,312,915Mar 31, 2024
AFFINITY ASSET ADVISORS, LLC5.10%2.51%2,642,519756,71740.13%20,241,696Mar 31, 2024
NEA MANAGEMENT COMPANY, LLC4.70%1.16%2,437,689--18,672,698Mar 31, 2024
VANGUARD GROUP INC4.67%0.00%2,419,02033,9981.43%18,529,693Mar 31, 2024
FMR LLC3.80%0.00%1,967,432-304,874-13.42%15,070,530Mar 31, 2024
SAMSARA BIOCAPITAL, LLC3.01%1.85%1,562,500--11,968,750Mar 31, 2024
SPHERA FUNDS MANAGEMENT LTD.2.65%1.48%1,372,907-190,000-12.16%10,516,468Mar 31, 2024
BLUE OWL CAPITAL HOLDINGS LP2.45%1.94%1,270,027--9,728,407Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC2.06%0.00%1,067,47934,7633.37%8,177,750Mar 31, 2024
WOODLINE PARTNERS LP1.71%0.06%888,067588,067196.02%6,802,593Mar 31, 2024
STATE STREET CORP1.70%0.00%880,639134,10617.96%6,745,695Mar 31, 2024
MILLENNIUM MANAGEMENT LLC1.36%0.00%703,606-207,859-22.80%5,389,622Mar 31, 2024
KNOTT DAVID M JR1.09%1.53%564,549--4,324,000Mar 31, 2024
KENNEDY CAPITAL MANAGEMENT LLC0.84%0.07%437,657150,12052.21%3,352,453Mar 31, 2024

Inozyme Pharma's largest institutional shareholder is ADAGE CAPITAL PARTNERS GP, L.L.C., holding 10.28% of the company's total share outstanding, currently valued at $40.82M. The top 10 institutional shareholders own together 66.49% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC8.67%22.13%4,494,851--34,430,559Mar 31, 2024
AFFINITY ASSET ADVISORS, LLC5.10%2.51%2,642,519756,71740.13%20,241,696Mar 31, 2024
BLUE OWL CAPITAL HOLDINGS LP2.45%1.94%1,270,027--9,728,407Mar 31, 2024
SAMSARA BIOCAPITAL, LLC3.01%1.85%1,562,500--11,968,750Mar 31, 2024
SOFINNOVA INVESTMENTS, INC.8.26%1.83%4,280,308--32,787,159Mar 31, 2024
EXOME ASSET MANAGEMENT LLC0.53%1.79%273,413273,413100.00%2,094,344Mar 31, 2024
KNOTT DAVID M JR1.09%1.53%564,549--4,324,000Mar 31, 2024
SPHERA FUNDS MANAGEMENT LTD.2.65%1.48%1,372,907-190,000-12.16%10,516,468Mar 31, 2024
NEA MANAGEMENT COMPANY, LLC4.70%1.16%2,437,689--18,672,698Mar 31, 2024
ROCK SPRINGS CAPITAL MANAGEMENT LP7.10%0.72%3,681,174--28,197,793Mar 31, 2024
SUPERSTRING CAPITAL MANAGEMENT LP0.22%0.57%112,739-11,205-9.04%863,581Mar 31, 2024
OVERBROOK MANAGEMENT CORP0.42%0.45%219,326--1,680,037Mar 31, 2024
EVENTIDE ASSET MANAGEMENT, LLC6.13%0.38%3,179,837--24,357,551Mar 31, 2024
SAMLYN CAPITAL, LLC5.62%0.37%2,912,913-459,645-13.63%22,312,915Mar 31, 2024
PARKMAN HEALTHCARE PARTNERS LLC0.43%0.21%222,94310,5114.95%1,707,743Mar 31, 2024
UBS OCONNOR LLC0.35%0.10%183,218-61,710-25.20%1,403,450Mar 31, 2024
GSA CAPITAL PARTNERS LLP0.25%0.08%131,098-35,906-21.50%1,004,000Mar 31, 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.10.28%0.08%5,328,856-208,644-3.77%40,819,037Mar 31, 2024
KENNEDY CAPITAL MANAGEMENT LLC0.84%0.07%437,657150,12052.21%3,352,453Mar 31, 2024
WOODLINE PARTNERS LP1.71%0.06%888,067588,067196.02%6,802,593Mar 31, 2024

The largest Inozyme Pharma shareholder by % of total assets is PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC. The company owns 4.49M shares of Inozyme Pharma (INZY), representing 22.13% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
AFFINITY ASSET ADVISORS, LLC5.10%2.51%2,642,519756,71740.13%20,241,696Mar 31, 2024
WOODLINE PARTNERS LP1.71%0.06%888,067588,067196.02%6,802,593Mar 31, 2024
EXOME ASSET MANAGEMENT LLC0.53%1.79%273,413273,413100.00%2,094,344Mar 31, 2024
WELLINGTON MANAGEMENT GROUP LLP0.47%0.00%244,200244,200100.00%1,870,572Mar 31, 2024
KENNEDY CAPITAL MANAGEMENT LLC0.84%0.07%437,657150,12052.21%3,352,453Mar 31, 2024
STATE STREET CORP1.70%0.00%880,639134,10617.96%6,745,695Mar 31, 2024
DIMENSIONAL FUND ADVISORS LP0.34%0.00%174,647110,962174.24%1,337,796Mar 31, 2024
PRELUDE CAPITAL MANAGEMENT, LLC0.12%0.03%62,44562,445100.00%478,329Mar 31, 2024
GOLDMAN SACHS GROUP INC0.79%0.00%409,92346,55112.81%3,140,010Mar 31, 2024
BLACKROCK INC.5.96%0.00%3,088,65346,3231.52%23,659,082Mar 31, 2024
CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD.0.07%0.00%34,83234,832100.00%266,813Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC2.06%0.00%1,067,47934,7633.37%8,177,750Mar 31, 2024
VANGUARD GROUP INC4.67%0.00%2,419,02033,9981.43%18,529,693Mar 31, 2024
BALYASNY ASSET MANAGEMENT L.P.0.06%0.00%31,38031,380100.00%240,371Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.06%-30,15430,154100.00%230,980Mar 31, 2024
JPMORGAN CHASE & CO0.12%-61,57727,24179.34%471,680Mar 31, 2024
BAILARD, INC.0.05%0.01%24,30024,300100.00%186,138Mar 31, 2024
AMERICAN CENTURY COMPANIES INC0.10%0.00%51,42722,73279.22%393,931Mar 31, 2024
LIDO ADVISORS, LLC0.03%0.00%17,10817,108100.00%131,047Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.03%-16,10016,100100.00%123,326Mar 31, 2024

As of Mar 31 2024, Inozyme Pharma's largest institutional buyer is AFFINITY ASSET ADVISORS, LLC. The company purchased 756.72K stocks of INZY, valued at $20.24M.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
SAMLYN CAPITAL, LLC5.62%0.37%2,912,913-459,645-13.63%22,312,915Mar 31, 2024
OCTAGON CAPITAL ADVISORS LP----400,000-100.00%-Mar 31, 2024
BIOIMPACT CAPITAL LLC----323,813-100.00%-Mar 31, 2024
FMR LLC3.80%0.00%1,967,432-304,874-13.42%15,070,530Mar 31, 2024
ADAGE CAPITAL PARTNERS GP, L.L.C.10.28%0.08%5,328,856-208,644-3.77%40,819,037Mar 31, 2024
MILLENNIUM MANAGEMENT LLC1.36%0.00%703,606-207,859-22.80%5,389,622Mar 31, 2024
SPHERA FUNDS MANAGEMENT LTD.2.65%1.48%1,372,907-190,000-12.16%10,516,468Mar 31, 2024
LAURION CAPITAL MANAGEMENT LP0.78%0.03%402,197-155,132-27.83%3,080,829Mar 31, 2024
CITADEL ADVISORS LLC0.18%0.00%92,718-66,745-41.86%710,220Mar 31, 2024
UBS OCONNOR LLC0.35%0.10%183,218-61,710-25.20%1,403,450Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.34%0.00%173,700-44,800-20.50%1,331,000Mar 31, 2024
GSA CAPITAL PARTNERS LLP0.25%0.08%131,098-35,906-21.50%1,004,000Mar 31, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC0.03%0.00%17,800-34,000-65.64%136,348Mar 31, 2024
SCHONFELD STRATEGIC ADVISORS LLC0.14%0.00%74,800-33,900-31.19%572,968Mar 31, 2024
BARCLAYS PLC0.07%0.00%36,909-32,215-46.60%282,000Mar 31, 2024
XTX TOPCO LTD----29,489-100.00%-Mar 31, 2024
TWO SIGMA ADVISERS, LP0.08%0.00%41,300-29,400-41.58%316,358Mar 31, 2024
TWO SIGMA INVESTMENTS, LP0.06%0.00%29,893-23,807-44.33%228,980Mar 31, 2024
JANE STREET GROUP, LLC0.06%-29,085-22,319-43.42%222,791Mar 31, 2024
BANK OF MONTREAL /CAN/----21,900-100.00%-Mar 31, 2024

As of Mar 31 2024, Inozyme Pharma's biggest institutional seller is SAMLYN CAPITAL, LLC. The company sold -0.46M shares of INZY, valued at $22.31M.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
EXOME ASSET MANAGEMENT LLC0.53%1.79%273,413273,413100.00%2,094,344Mar 31, 2024
WELLINGTON MANAGEMENT GROUP LLP0.47%0.00%244,200244,200100.00%1,870,572Mar 31, 2024
PRELUDE CAPITAL MANAGEMENT, LLC0.12%0.03%62,44562,445100.00%478,329Mar 31, 2024
CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD.0.07%0.00%34,83234,832100.00%266,813Mar 31, 2024
BALYASNY ASSET MANAGEMENT L.P.0.06%0.00%31,38031,380100.00%240,371Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.06%-30,15430,154100.00%230,980Mar 31, 2024
BAILARD, INC.0.05%0.01%24,30024,300100.00%186,138Mar 31, 2024
LIDO ADVISORS, LLC0.03%0.00%17,10817,108100.00%131,047Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.03%-16,10016,100100.00%123,326Mar 31, 2024
RESOURCES INVESTMENT ADVISORS, LLC.0.03%0.00%13,65013,650100.00%104,559Mar 31, 2024
ENTRYPOINT CAPITAL, LLC0.00%0.01%1,4601,460100.00%11,184Mar 31, 2024
BFSG, LLC0.00%0.00%500500100.00%3,830,000Mar 31, 2024
SIGNATUREFD, LLC0.00%-113113100.00%866,000Mar 31, 2024
ICA GROUP WEALTH MANAGEMENT, LLC0.00%0.00%8585100.00%651Mar 31, 2024
GAMMA INVESTING LLC0.00%0.00%4848100.00%368Mar 31, 2024
NISA INVESTMENT ADVISORS, LLC--2424100.00%184,000Mar 31, 2024
NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC--99100.00%68Mar 31, 2024

Inozyme Pharma's largest new institutional shareholder by number of shares is EXOME ASSET MANAGEMENT LLC, purchased 273.41K shares, valued at $2.09M, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
OCTAGON CAPITAL ADVISORS LP----400,000-100.00%-Mar 31, 2024
BIOIMPACT CAPITAL LLC----323,813-100.00%-Mar 31, 2024
XTX TOPCO LTD----29,489-100.00%-Mar 31, 2024
BANK OF MONTREAL /CAN/----21,900-100.00%-Mar 31, 2024
ENGINEERS GATE MANAGER LP----14,519-100.00%-Mar 31, 2024
VALUES FIRST ADVISORS, INC.----13,898-100.00%-Mar 31, 2024
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM----12,399-100.00%-Mar 31, 2024
BANK OF AMERICA CORP /DE/----5,000-100.00%-Mar 31, 2024

Inozyme Pharma's largest sold out institutional shareholder by shares sold is OCTAGON CAPITAL ADVISORS LP, sold -0.40M shares, valued at -, as of undefined.

Inozyme Pharma Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
VANGUARD VALLEY FORGE FUNDS0.06%29,430--Dec 31, 2023
FIDELITY SELECT PORTFOLIOS0.02%1,515,687-751,500-33.15%Feb 29, 2024
BRIDGEWAY FUNDS INC0.02%48,400-39,883-45.18%Dec 29, 2023
TIAA SEPARATE ACCOUNT VA 10.02%4,356--Dec 31, 2023
BlackRock Advantage SMID Cap Fund, Inc.0.02%3,382--Dec 29, 2023
DEUTSCHE DWS INVESTMENTS VIT FUNDS0.02%7,2061,92436.43%Dec 31, 2023
QUANTITATIVE MASTER SERIES LLC0.01%56,742--Dec 31, 2023
VANGUARD INDEX FUNDS0.01%2,711,204710,76835.53%Dec 31, 2023
ALPS ETF Trust0.00%45,70545,705-Feb 29, 2024
JPMORGAN INSURANCE TRUST0.00%37,800--Mar 31, 2023
FIDELITY CONCORD STREET TRUST0.00%439,47237,7609.40%Feb 29, 2024
Calvert Variable Products, Inc.0.00%4,8052,01071.91%Dec 31, 2023
AdvisorShares Trust0.00%3,445--Dec 29, 2023
Voya INVESTORS TRUST0.00%61,800--Dec 31, 2023
GOLDMAN SACHS VARIABLE INSURANCE TRUST0.00%3,8493,849-Dec 31, 2023
MUTUAL FUND SERIES TRUST0.00%3,179,83754,8371.75%Dec 31, 2023
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%22,831--Dec 31, 2023
Voya VARIABLE PORTFOLIOS INC0.00%20,0806,39546.73%Dec 31, 2023
STATE STREET VARIABLE INSURANCE SERIES FUNDS INC0.00%1,990--Dec 31, 2023
AMERICAN CENTURY ETF TRUST0.00%33,81011,88654.21%Feb 29, 2024
STATE STREET INSTITUTIONAL INVESTMENT TRUST0.00%21,90011,500110.58%Dec 31, 2023
NATIONWIDE MUTUAL FUNDS0.00%30,09924,407428.79%Jan 31, 2024
TIAA-CREF LIFE FUNDS0.00%608--Dec 31, 2023
RUSSELL INVESTMENT CO0.00%64,806--Jan 31, 2024
SCHWAB STRATEGIC TRUST0.00%34,074--Feb 29, 2024
VARIABLE INSURANCE PRODUCTS FUND II0.00%2,32344323.56%Dec 31, 2023
RUSSELL INVESTMENT FUNDS0.00%10,935--Dec 31, 2023
T. Rowe Price Index Trust, Inc.0.00%2,916--Feb 29, 2024
VANGUARD WELLINGTON FUND0.00%53,040--Feb 29, 2024
SunAmerica Specialty Series0.00%67--Apr 30, 2021
iSHARES TRUST0.00%1,782,312--Feb 29, 2024
VANGUARD SCOTTSDALE FUNDS0.00%210,33779,98461.36%Feb 29, 2024
NATIONWIDE VARIABLE INSURANCE TRUST0.00%13,3768,444171.21%Dec 31, 2023
Legg Mason ETF Investment Trust0.00%2,810--Dec 31, 2023
EQ ADVISORS TRUST0.00%98,90729,33042.15%Dec 31, 2023
RYDEX SERIES FUNDS0.00%309--Dec 31, 2023
ProFunds0.00%68027969.58%Jan 31, 2024
Dimensional ETF Trust0.00%30,0555,19920.92%Jan 31, 2024
VALIC Co I0.00%18,3215,27940.48%Feb 29, 2024
PENN SERIES FUNDS INC0.00%1,300--Dec 29, 2023
NORTHERN FUNDS0.00%37,3957,18423.78%Dec 29, 2023
RYDEX DYNAMIC FUNDS0.00%153--Dec 31, 2023
DFA INVESTMENT DIMENSIONS GROUP INC0.00%34,89525,045254.26%Jan 31, 2024
PROSHARES TRUST0.00%6,9962,62660.09%Feb 29, 2024
MORGAN STANLEY PATHWAY FUNDS0.00%2,6351,530138.46%Feb 29, 2024
PGIM ETF TRUST0.00%1,442--Feb 29, 2024
RYDEX VARIABLE TRUST0.00%20--Dec 31, 2023
SUNAMERICA SERIES TRUST0.00%5,4091,55940.49%Jan 31, 2024
COLLEGE RETIREMENT EQUITIES FUND0.00%16,918--Dec 31, 2023
Guggenheim Active Allocation Fund0.00%85--Feb 29, 2024
Brinker Capital Destinations Trust0.00%828828-Feb 29, 2024
LINCOLN VARIABLE INSURANCE PRODUCTS TRUST0.00%28,500--Dec 31, 2023
Blackstone Alternative Investment Funds0.00%1,600-200-11.11%Dec 31, 2023
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%24,2379,94969.63%Dec 31, 2023
MASTER INVESTMENT PORTFOLIO0.00%892--Dec 31, 2023
Advisors' Inner Circle Fund III0.00%133133-Jan 31, 2024
Brighthouse Funds Trust II0.00%16,8615,39046.99%Dec 31, 2023
PACIFIC SELECT FUND0.00%20,2266,27745.00%Dec 31, 2023
Bridge Builder Trust0.00%19,7056,76552.28%Dec 31, 2023
BlackRock Variable Series Funds, Inc.0.00%6,4842,38758.26%Dec 31, 2023
MASSMUTUAL SELECT FUNDS0.00%1,299--Dec 31, 2023
John Hancock Funds II0.00%2,067--Feb 29, 2024
SEI INSTITUTIONAL INVESTMENTS TRUST0.00%3,069--Feb 29, 2024

Inozyme Pharma's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 29.43K shares, compromising 0.06% of its total assets.

Inozyme Pharma Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 249112.35%
31 Dec, 23812.53%
30 Sep, 23798.22%
30 Jun, 237346.00%
31 Mar, 235038.89%
31 Dec, 2236-
30 Sep, 2236-16.28%
30 Jun, 2243-10.42%
31 Mar, 2248-4.00%
31 Dec, 2150-1.96%
30 Sep, 21514.08%
30 Jun, 2149-7.55%
31 Mar, 2153-1.85%
31 Dec, 20548.00%
30 Sep, 2050-

As of 31 Mar 24, 91 institutions are holding Inozyme Pharma's shares, representing an increase of 12.35% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 2449,874,140-0.24%
31 Dec, 2349,993,2502.67%
30 Sep, 2348,693,88742.74%
30 Jun, 2334,113,6236.75%
31 Mar, 2331,956,2189.88%
31 Dec, 2229,083,364-5.69%
30 Sep, 2230,838,268-2.25%
30 Jun, 2231,549,65281.24%
31 Mar, 2217,407,9360.45%
31 Dec, 2117,329,750-0.52%
30 Sep, 2117,419,787-11.65%
30 Jun, 2119,717,1103.33%
31 Mar, 2119,081,5863.92%
31 Dec, 2018,361,43812.74%
30 Sep, 2016,286,311-

Inozyme Pharma (INZY) has 49.87M shares outstanding as of 31 Mar 24, down -0.24% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 2496.21%1.24%
31 Dec, 2388.08%0.75%
30 Sep, 23108.55%1.78%
30 Jun, 2378.03%1.46%
31 Mar, 2373.09%1.23%
31 Dec, 2277.02%1.54%
30 Sep, 2270.64%1.12%
30 Jun, 2279.46%1.47%
31 Mar, 2273.49%1.36%
31 Dec, 2173.56%1.36%
30 Sep, 2173.68%1.05%
30 Jun, 2183.94%1.27%
31 Mar, 2181.44%0.79%
31 Dec, 20101.44%1.25%
30 Sep, 2089.97%-

As of 31 Mar 24, Inozyme Pharma is held by 96.21% institutional shareholders, representing a 1.24% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 2442-20.75%
31 Dec, 235323.26%
30 Sep, 2343-24.56%
30 Jun, 235762.86%
31 Mar, 2335118.75%
31 Dec, 221623.08%
30 Sep, 2213-55.17%
30 Jun, 222945.00%
31 Mar, 2220-16.67%
31 Dec, 2124-
30 Sep, 2124-
30 Jun, 2124-4.00%
31 Mar, 2125-19.35%
31 Dec, 2031-38.00%
30 Sep, 2050-

42 institutional shareholders have increased their position in INZY stock as of 31 Mar 24 compared to 53 in the previous quarter (a -20.75% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 2430114.29%
31 Dec, 2314-30.00%
30 Sep, 2320100.00%
30 Jun, 2310100.00%
31 Mar, 235-54.55%
31 Dec, 2211-21.43%
30 Sep, 221416.67%
30 Jun, 2212-29.41%
31 Mar, 221721.43%
31 Dec, 2114-
30 Sep, 21147.69%
30 Jun, 211318.18%
31 Mar, 211157.14%
31 Dec, 207-
30 Sep, 20--

30 institutional shareholders have reduced their position in INZY stock as of 31 Mar 24 compared to 14 in the previous quarter (a 114.29% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 249112.35%49,874,140-0.24%96.21%1.24%42-20.75%30114.29%
31 Dec, 23812.53%49,993,2502.67%88.08%0.75%5323.26%14-30.00%
30 Sep, 23798.22%48,693,88742.74%108.55%1.78%43-24.56%20100.00%
30 Jun, 237346.00%34,113,6236.75%78.03%1.46%5762.86%10100.00%
31 Mar, 235038.89%31,956,2189.88%73.09%1.23%35118.75%5-54.55%
31 Dec, 2236-29,083,364-5.69%77.02%1.54%1623.08%11-21.43%
30 Sep, 2236-16.28%30,838,268-2.25%70.64%1.12%13-55.17%1416.67%
30 Jun, 2243-10.42%31,549,65281.24%79.46%1.47%2945.00%12-29.41%
31 Mar, 2248-4.00%17,407,9360.45%73.49%1.36%20-16.67%1721.43%
31 Dec, 2150-1.96%17,329,750-0.52%73.56%1.36%24-14-
30 Sep, 21514.08%17,419,787-11.65%73.68%1.05%24-147.69%
30 Jun, 2149-7.55%19,717,1103.33%83.94%1.27%24-4.00%1318.18%
31 Mar, 2153-1.85%19,081,5863.92%81.44%0.79%25-19.35%1157.14%
31 Dec, 20548.00%18,361,43812.74%101.44%1.25%31-38.00%7-
30 Sep, 2050-16,286,311-89.97%-50---

Inozyme Pharma Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 03, 2024Treco Douglas Adirector, officer CEOS-SaleSell7,523$6.94$52.21K20,665
Aug 03, 2023Pivotal bioVenture Partners Fund I, L.P.director-P-PurchaseBuy119,048$4.80$571.43K2,923,110
Aug 03, 2023Pivotal bioVenture Partners Fund I, L.P.director-P-PurchaseBuy714,285$4.80$3.43M1,571,741
Aug 03, 2023Hopfner Robert Lornedirector-P-PurchaseBuy119,048$4.80$571.43K2,923,110
Aug 03, 2023Hopfner Robert Lornedirector-P-PurchaseBuy714,285$4.80$3.43M1,571,741
May 15, 2023Hopfner Robert Lornedirector-P-PurchaseBuy228,702$6.25$1.43M3,661,518

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 03, 2023Pivotal bioVenture Partners Fund I, L.P.director-P-PurchaseBuy119,048$4.80$571.43K2,923,110
Aug 03, 2023Pivotal bioVenture Partners Fund I, L.P.director-P-PurchaseBuy714,285$4.80$3.43M1,571,741
Aug 03, 2023Hopfner Robert Lornedirector-P-PurchaseBuy119,048$4.80$571.43K2,923,110
Aug 03, 2023Hopfner Robert Lornedirector-P-PurchaseBuy714,285$4.80$3.43M1,571,741
May 15, 2023Hopfner Robert Lornedirector-P-PurchaseBuy228,702$6.25$1.43M3,661,518

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 03, 2024Treco Douglas Adirector, officer CEOM-ExemptSell25,000--75,000
Apr 03, 2024Treco Douglas Adirector, officer CEOS-SaleSell7,523$6.94$52.21K20,665

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 03, 2024Treco Douglas Adirector, officer CEOM-ExemptSell25,000--75,000
Apr 03, 2024Treco Douglas Adirector, officer CEOM-ExemptBuy25,000--28,188
Apr 03, 2024Treco Douglas Adirector, officer CEOS-SaleSell7,523$6.94$52.21K20,665
Apr 03, 2024Winton Matthewofficer COOA-AwardBuy3,188$3.33$10.62K3,188
Mar 15, 2024Winton Matthewofficer COOA-AwardBuy175,000$5.77$1.01M175,000
Mar 15, 2024Treco Douglas Adirector, officer CEOA-AwardBuy300,000$5.77$1.73M300,000
Mar 15, 2024Subramanian Sanjayofficer SVP, CFOA-AwardBuy165,000$5.77$952.05K165,000
Oct 03, 2023Subramanian Sanjayofficer SVP, CFOA-AwardBuy2,319$3.57$8.28K30,398
Aug 03, 2023Pivotal bioVenture Partners Fund I, L.P.director-P-PurchaseBuy119,048$4.80$571.43K2,923,110
Aug 03, 2023Pivotal bioVenture Partners Fund I, L.P.director-P-PurchaseBuy714,285$4.80$3.43M1,571,741
Aug 03, 2023Hopfner Robert Lornedirector-P-PurchaseBuy119,048$4.80$571.43K2,923,110
Aug 03, 2023Hopfner Robert Lornedirector-P-PurchaseBuy714,285$4.80$3.43M1,571,741
Jun 15, 2023Mathers Edward Tdirector-A-AwardBuy16,000$6.18$98.88K16,000
Jun 15, 2023Sullivan Lynne Mariedirector-A-AwardBuy16,000$6.18$98.88K16,000
Jun 15, 2023DIAZ REINALDO Mdirector-A-AwardBuy16,000$6.18$98.88K16,000
Jun 15, 2023Hopfner Robert Lornedirector-A-AwardBuy16,000$6.18$98.88K16,000
Jun 15, 2023Bolte Axeldirector-A-AwardBuy16,000$6.18$98.88K16,000
Jun 15, 2023Edwards Martindirector-A-AwardBuy16,000$6.18$98.88K16,000
Jun 15, 2023Bhagat Sarah Mdirector-A-AwardBuy16,000$6.18$98.88K16,000
May 15, 2023Hopfner Robert Lornedirector-P-PurchaseBuy228,702$6.25$1.43M3,661,518

The last insider sell of Inozyme Pharma's stock was made by Treco Douglas A on Apr 03 2024, selling 25,000 shares at - per share (valued at -). The last insider buy of INZY was made by Pivotal bioVenture Partners Fund I, L.P. on Aug 03 2023, buying 119,048 shares at $4.80 per share (worth $571.43K).

Inozyme Pharma Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 20241250.00%
Q1 20244--
Q3 20235--
Q2 202313--
Q1 20236--
Q4 20221--
Q3 20222--
Q2 202220--
Q1 20223--
Q2 202192450.00%
Q1 20211211200.00%
Q3 2020535498.15%

1 total buy trades, and 2 total sell trades (buy/sell ratio of 0.50%) were made by Inozyme Pharma's insiders, as of Q2 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 2024-1-
Q1 2024---
Q3 20234--
Q2 20232--
Q1 20233--
Q4 20221--
Q3 2022---
Q2 20228--
Q1 2022---
Q2 2021-1-
Q1 2021-1-
Q3 202016--

As of Q2 2024, Insider owners conducted 0 open market buy trades and 1 open market sell trades of Inozyme Pharma's stocks.

Inozyme Pharma Peer Ownership


TickerCompany
TERNTerns Pharmaceuticals, Inc.
ABOSAcumen Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
XFORX4 Pharmaceuticals, Inc.
ELDNEledon Pharmaceuticals, Inc.
DAWNDay One Biopharmaceuticals, Inc.
PDSBPDS Biotechnology Corporation
AMLXAmylyx Pharmaceuticals, Inc.
HOOKHOOKIPA Pharma Inc.

INZY Ownership FAQ


Inozyme Pharma is owned by institutional shareholders (96.21%), insiders (0.52%), and public (3.27%). The largest institutional shareholder of Inozyme Pharma is ADAGE CAPITAL PARTNERS GP, L.L.C. (10.28% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.06% of total shares).

Inozyme Pharma's major institutional shareholders are ADAGE CAPITAL PARTNERS GP, L.L.C., PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC, SOFINNOVA INVESTMENTS, INC., ROCK SPRINGS CAPITAL MANAGEMENT LP, and EVENTIDE ASSET MANAGEMENT, LLC. The top five shareholders own together 40.44% of the company's share outstanding.

As of Mar 2024, there are 91 institutional shareholders of Inozyme Pharma.

ADAGE CAPITAL PARTNERS GP, L.L.C owns 5.33M shares of Inozyme Pharma, representing 10.28% of the company's total shares outstanding, valued at $40.82M (as of Mar 2024).

As of Mar 2024, PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC holds 4.49M shares of Inozyme Pharma (INZY), compromising 8.67% of the company, valued at $34.43M.

SOFINNOVA INVESTMENTS, INC is the third largest holder of Inozyme Pharma. The company owns 4.28M of the company's shares outstanding (worth $32.79M).